Voyager Therapeutics (VYGR) Assets (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Assets data on file, last reported at $219.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 37.91% year-over-year to $219.3 million; the trailing twelve-month figure through Mar 2026 stood at $219.3 million (down 37.91% YoY), and the FY2025 full-year result was $252.3 million, down 35.81% from the prior year.
• Assets slipped to $219.3 million in Q1 2026, from $252.3 million in the prior quarter.
• In the past five years, Assets ranged from a high of $469.6 million in Q1 2024 to a low of $159.4 million in Q4 2022.
• A 5-year average of $306.6 million and a median of $315.5 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets soared 120.44% in 2023 and tumbled 37.91% in 2026, its largest moves.
• Tracing VYGR's Assets over 5 years: stood at $159.4 million in 2022, then soared by 120.44% to $351.3 million in 2023, then rose by 11.89% to $393.0 million in 2024, then sank by 35.81% to $252.3 million in 2025, then declined by 13.06% to $219.3 million in 2026.
• Business Quant data shows VYGR's Assets at $219.3 million in Q1 2026, $252.3 million in Q4 2025, and $288.3 million in Q3 2025.